Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report
Laura Ballotta(Azienda Sanitaria Universitaria Integrata di Trieste), Roberto Marasca(University of Modena and Reggio Emilia), Lorenzo De Paoli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluigi Reda(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonio Cuneo(Arcispedale Sant'Anna), Lorella Orsucci(Azienda Ospedaliero Universitaria San Giovanni Battista), Monica Maccaferri(Azienda Ospedaliero-Universitaria di Modena), Federico Chiurazzi(University of Naples Federico II), Daniela Gottardi(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Robin Foà(Sapienza University of Rome)
Cited by 2
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553